David D. House

Senior Vice President, Finance and Principal Financial Officer, Armata Pharmaceuticals, Inc.

A later filing names a successor. First published here October 28, 2026; built from records as of October 28, 2026.

David D. House signed the annual report of Armata Pharmaceuticals, Inc. on Form 10-K as Senior Vice President, Finance and Principal Financial Officer, filed March 25, 2026.¹ A later filing by Armata Pharmaceuticals, Inc., made on July 20, 2026, names David House as its chief financial officer; the record holds no filing that reports the end of David D. House's tenure.

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Armata Pharmaceuticals, Inc. (ARMP) Biological Products, (No Diagnostic Substances)	Senior Vice President, Finance and Principal Financial Officer	A later filing names a successor David House, filed July 20, 2026 (filing)	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

March 25, 202610-K filed
David D. House signed the annual report of Armata Pharmaceuticals, Inc. on Form 10-K as Senior Vice President, Finance and Principal Financial Officer, filed March 25, 2026.
/s/ David D. House Senior Vice President, Finance and Principal Financial Officer
[1] Annual report on Form 10-K by Armata Pharmaceuticals, Inc., filed with the SEC on March 25, 2026. Read the filing. The record at CFO Tribune.

Sources

Annual report on Form 10-K, Armata Pharmaceuticals, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 25, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or David D. House wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.